Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €59.03 EUR
Change Today -1.57 / -2.59%
Volume 0.0
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

prothena corp plc (0PT) Snapshot

Open
€60.42
Previous Close
€60.60
Day High
€60.42
Day Low
€59.03
52 Week High
07/23/15 - €63.13
52 Week Low
08/1/14 - €12.65
Market Cap
1.8B
Average Volume 10 Days
151.1
EPS TTM
--
Shares Outstanding
31.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTHENA CORP PLC (0PT)

Related News

No related news articles were found.

prothena corp plc (0PT) Related Businessweek News

No Related Businessweek News Found

prothena corp plc (0PT) Details

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion in Ireland. The company’s product pipeline includes NEOD001, a product candidate that is in Phase III clinical trials to treat patients with AL amyloidosis, as well as is in Phase I/II clinical trials for AL amyloidosis and persistent organ dysfunction. It is also developing PRX002 that is in Phase I clinical trials for the treatment of Parkinson’s disease and other synucleinopathies; and PRX003, a monoclonal antibody for psoriasis and other inflammatory diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

46 Employees
Last Reported Date: 03/13/15
Founded in 2012

prothena corp plc (0PT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $491.7K
Chief Financial Officer
Total Annual Compensation: $338.3K
Chief Scientific Officer and Head of Research...
Total Annual Compensation: $398.3K
Chief Medical Officer
Total Annual Compensation: $348.5K
Chief Legal Officer
Total Annual Compensation: $217.9K
Compensation as of Fiscal Year 2014.

prothena corp plc (0PT) Key Developments

Prothena Corporation plc Appoints Anders Härfstrand to its Board of Directors

Prothena Corporation plc announced the appointment of Anders Härfstrand, MD, PhD, to its Board of Directors. Anders' wealth of strategic expertise leading both entrepreneurial and large commercial organizations will serve as a valuable asset as continue development of pipeline of potential therapies, and in particular as move NEOD001 towards commercialization. Dr. Härfstrand was most recently the CEO of BBB Therapeutics BV.

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease

Prothena Corporation plc presented clinical results from a Phase 1 single ascending dose study of PRX002, a monoclonal antibody for the potential treatment of Parkinson's disease and other related synucleinopathies. PRX002 is the focus of a worldwide collaboration between Prothena and Roche. Presented Presented now as part of the late breaking session at the 19thInternational Congress of Parkinson's Disease and Movement Disorders, the data demonstrated that PRX002 was safe and well-tolerated in healthy volunteers, meeting the primary objective of the study. Further, results from this study showed that administration of PRX002 led to a mean reduction of free serum alpha-synuclein levels of up to 96%. These overall results were highly statistically significant (p < 0.00001). Reduction of free serum alpha-synuclein, a protein potentially involved in the onset and progression of Parkinson's disease and the target of PRX002, was shown to be robust, rapid, and dose- and time-dependent after a single dose. The Phase 1 double-blind, placebo-controlled, single ascending dose study enrolled 40 healthy volunteers. All volunteers enrolled were randomized 3:1 into five escalating dose cohorts (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg or 30 mg/kg) to receive either PRX002 or placebo. No serious adverse events or hypersensitivity reactions were reported. PRX002 demonstrated favorable pharmacokinetic properties, supporting the current dosing frequency in the on-going Phase 1 multiple ascending dose study in patients with Parkinson's disease. Treatment-emergent adverse events in greater than 5% of subjects were vessel puncture site pain, headache, viral infection, nausea, neutropenia, upper respiratory infection and pruritus. All PRX002-related adverse events were mild and no dose limiting toxicities were observed. No anti-drug antibodies were detected.

Prothena Corporation plc Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases

Prothena Corporation plc announced the successful first human dosing in a Phase 1 clinical trial of its proprietary protein immunotherapy, PRX003. PRX003 is a monoclonal antibody targeting melanoma cell adhesion molecule for the potential treatment of psoriasis and other inflammatory diseases. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose study designed to assess the safety, tolerability, pharmacokinetics and immunogenicity of PRX003. Prothena plans to enroll up to 40 subjects in the U.S. PRX003 is a monoclonal antibody for the potential treatment of psoriasis and other inflammatory diseases. Within the immune system, Th-17 white blood cells initiate the body's response to infections, and are known to be a key participant in both normal inflammatory reactions and autoimmune diseases. MCAM is expressed on the surface of Th-17 cells, and allows certain cells traveling in the blood stream to leave the circulation and enter tissues, primarily to initiate or continue a disease process. PRX003 is designed to block MCAM and not allow the migration of these pathogenic cells into tissues. PRX003 may be useful for treating a variety of inflammatory diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, sarcoidosis, uveitis, vasculitis, and Behcet's disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
0PT:GR €59.03 EUR -1.57

0PT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 0PT.
View Industry Companies
 

Industry Analysis

0PT

Industry Average

Valuation 0PT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 95.1x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 94.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit www.prothena.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.